CV Shafiee Ardestani new

CURRICULUM VITA
Personal Characteristics:
Name: Mehdi Shafiee Ardestani
Date of Birth: 29.November.1982, IRAN
Sex: Male
Iran Id. card No.:3289
Mobile Phone: +98-09128267629
Tel/Fax: + 98-21-66953311
Marital Status: Married
To whom correspondence should be addressed at:
Department of Hepatitis B and HIV and Nanobiotechnology
And R & D
Pasteur Institute of Iran, Tehran, Tehran, Iran
mehdishafieea@aol.com
shafieeardestani@gmail.com
shafieeardestani@yahoo.com
m_shafiee@pasteur.ac.ir
Current Position:
Assistant Professor of Nano-Pharmaceutical and Radiopharmacological Sciences,
Pasteur Institute of Iran

EDUCATION
Pharm.D. (Doctorate in Pharmacy).
PhD. (Radiopharmaceutical Chemistry),
Post Doctoral fellowship in Nanopharmaceutical Sciences
INSTRUMENTATION-TECHNIQUE EXPERIENCES:
-Nanomedical experiences especially nano-drug targeting
- HPLC
- UV/Visible Spectroscopy
- IR Spectroscopy
- Stereotaxic Surgery
- Microdialysis
- cannula implantation in the brain and spinal cord for drug delivery purposes
-Patch clamp, Current clamp and voltage clamp
- The use of Electrical Lesion Maker for demolishing the special area in the brain
- [ Electrophysiology]
- Working with Gamma counter
-Iodine/ 99m Tc-labeling
-Gd-labeling, T 1 relaxation time measurment & MRI Imaging
-Quality controls of 99m Tc radiopharmaceuticals
- Vaccine production and formulation
Research Activities and Experiences:
A. Dissertations
1. Title of Pharm.D Thesis:
Effects of COX-2 and COX-2 gene expression inhibitors on memory-movement disorders and striatal
neurotransmissions in normal and rat model of Parkinson's
disease.
[Grant no. 84U60]
This study was supervised by Professor Hf Moghaddam and Professor AA Hemmati.
2. PhD thesis title:
With Supervision by:
Dr Amanlou, Professor Alavi and Dr Sadat Ebrahimi
Synthesis, in vitro and in vivo evaluations of Gadolinium-glycosilated compounds as novel cancer contrast media
agents for MR imaging
TEACHING EXPERIENCES:
1- General Chemistry: Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran
2- Organic Chemistry: Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran
3- Medicinal Chemistry: Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran,
4- Instrumentation: Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.

Thesis supervisor:
More than 6 Pharmacy doctorate, 16 Master degree (Molecular Biology, Biochemistry, Microbiology Biophysics
and …) and 4 PhD thesis (Biotechnology and
Radiopharmacological Sciences)
Awards:
[Yong scientist traveling grant] selected by the editorial board of XXXVI International
Congress of Pharmaceutical Sciences. Kyoto,
Japan
Graduation with the First and Best degree in Board Examination of Radiopharmacy-2009
The Best Iranian Student of the Year 2009 [Receiving the award from the Mr. President]
First degree in PhD Course of Radiopharmacy Entrance-2006
The First Young Scientist of University of Medical Sciences, 2005
Editorial board member:
International Journal of Pharmacy and Pharmaceutical Sciences (JAPAN)
Advisory board:
ASIAN JOURNAL OF PHARMACEUTICAL AND BIOLOGICAL RESEARCH (SINGAPORE)
MAGNETIC RESONANCE INSIGHTS (SWEDEN)
PERSPECTIVES IN MEDICINAL CHEMISTRY (SWEDEN)
JOURNAL OF PHARMACY AND CLINICAL SCIENCES (INDIA)
Reviewing articles as a referee for:
International Journal of Nanomedicine (U.S.A)
IRANIAN JOURNAL OF NUCLEAR MEDICINE (IRAN)
IRANIAN JOURNAL OF PHARMACEUTICAL RESEARCHES (IRAN)
JOURNAL OF PHARMACY RESEARCH (INDIA)
IRANIAN JOURNAL OF BASIC MEDICAL SCIENCES (IRAN)
African Journal of Pharmacy and Pharmacology (Africa)
Journal of Metabolomics (USA)
Pharm.D Thesis under my co-supervision
Synthesis & preliminary evaluation of glucose-tamoxifen porphyrin as a novel anti cancer agent
By Zahra Heidary, Pharmacy Doctorate student, TUMS, Tehran, Iran
Elham Hashemi, Mona Mosayebniya, Mojgan Mashayekhi, Mohammad Tadayonnezhad, Amir Javidi are Pharm.D
students who are continuing their thesis under my co-supervision at TUMS, Tehran, Iran
Active-In Progress Researches:
1-Synthesis & evaluation of DTPA-Levodopa) n=1,2,3 -Gd 3+ as a novel dopaminergic receptor imaging
agent for MRI
2-Synthesis & evaluation of Levodopa -Alendronate-Gd 3+ as a novel dopaminergic receptor imaging
agent for MRI
3-Liposome & polymer labeling with Gadolinium for non invasive pharmacokinetic investigation using
MRI
4-Synthesis of asparagines DTPA-Gd3 + as novel tumor MR imaging agent
5-Synthesis of anti-constipation derivatives from thebaine-drived compounds with aryl-maleimides
[Grant No: 8077]
6-Synthesis & preliminary evaluation of Gd 3+ -glucose-tamoxifen porphyrin as a novel Breast Cancer MR
imaging agent
7-Synthesis & investigation of special Gd 3+ -nano- polymer using the different labeling methods for lymphoma tumor
MR imaging {A part of PhD thesis]
8-Cancer cell inducing to provide animal models [A part of PhD thesis]
9-Synthesis, preclinical & clinical imaging of the novel iodinated ethylen diamine as novel melanoma MR imaging
agent
10. Evaluation of the Trp-DTPA-Gd complex as a possible cancer MRI agent
11. As 3+- DTPA-DG; novel anti-cancer agent.
12. DTPA-career based design (more than 4 Pharm.D Thesis) &…
13. Vaccine Formulations (DTP-Hib), (DTP-HB) Vaccine conjugation, Nano-drug targeting
14. Bioconjugation and anti cancer drugs

B. Publications:
[1] Shafiee Ardestani M et al 2005. Study of COX-2 inhibitors on rigidity of psudoparkinsonism induced by perphenazin
in comparisons with bromocriptine in rat. 11 th congress of pharmaceutical sciences,Shiraz
.Abstract book. page. 142 .
[2] Shafiee Ardestani M et al 2007. Selective and Nonselective COX-2 Inhibitors Improved the Rigidity Caused by Electrical
Lesion Toxicity in Substantia Nigra Neurons. The 9 th Iranian Congress of Toxicology May 15-17, 2007
Printed in Iranian Journal of Pharmaceutical Sciences, 2007, p (54) P118.
[3] Shafiee Ardestani, M et al., 2007. Effects of Dexamethasone and Betamethasone as COX-2 gene expression inhibitors on
rigidity in a rat model of Parkinson's disease. Indian. J. Pharmacol. 39: 235-239.
[4] Shafiee Ardestani, M et al. 2007. Effects of Aspirin and Celecoxib on rigidity in a rat model of Parkinson's disease. J. Biol.
Sci, 21: 3853-3858.
[5] Shafiee Ardestani , M et al. 2008. Effect of compound 11g as novel selective COX-2 inhibitor on movement disorders. J Med
Sci, Vol. 24 No. 3 436-441
[6] Shafiee Ardestani, M et al. 2008. COX inhibition: Catalepsy and Striatum Dopaminergic-GABAergic-Glutamatergic
Neurotransmission. Nature Precedings, DOI: 10101/npre.2008.1481.1
[7] Shafiee Ardestani , M et al. 2008 .Dopaminergic but not glutamatergic neurotransmission is increased in the striatum after
selective COX-2 inhibition in normal and hemiparkinsonian rats. Basic. Clin. Pharmcol. Toxicol,.2008; 103 , 293–296
[8] Shafiee Ardestani , M et al. 2008. Betamethasone can significantly decrease level of striatal glutamate in animal model of
Parkinson’s disease. Iranian J Pharm Res 2008 vol 7, issue 3; 299-232.
[9] Shafiee Ardestani , M et al. 2008. Steroidal anti inflammatory drug betamethasone significantly alters level of striatal
dopamine in a rat model of Parkinson’s disease. Nature Precedings. Doi:10.1038/npre.2008.2330.1
[10] Shafiee Ardestani M et al. 2008. Selective COX-2 but not COX-1 inhibition improves haloperidol induced catatonia by
enhancing the Striatum dopaminergic neurotransmission. J Pak Med Assoc. Accepted and in press.
[11] Shafiee Ardestani M et al 2008. Electrical lesion of Substantia nigra pars compacta; an alternative and convenient way to
generate the animal model of Parkinson’s disease J Pharmacol Therapeutics. 2008. Accepted, in press, Now Abstract is
available online
[12] Shafiee Ardestani, M et al 2008. Formulation and in vitro Evaluation of Eudragit L100 piroxicam. Nature Precedings
doi:10.1038/npre.2008.1544.1
[13] Shafiee Ardestani M et al 2008. Simultaneous determination of preservatives (Sodium benzoate and Potassium sorbate) in
soft drinks and extracts. Under Review J Anal Chem
[14] Mehdi Shafiee-Ardestani M et al. 2009. Preventive effect of ciprofloxacin on iron overload. In Press in
Journal of Hematology.
[15] Shafiee Ardestani M et al. 2008. Effect of Cyclooxygenase-2 inhibition on rigidity of animal model of Parkinson''s
disease. Tehran University Medical Journal; Vol. 66, No. 5, Aug 309-314
[16]
Shafiee Ardestani M et al 2008.
ُSteroidal anti inflammatory drugs improve the movement disorders
Accepted 2008. ISAC [ International Symposium of Analytical Cytology] Budapest, Hungary Abstract Book Pages: 136-138
[17] Shafiee Ardestani M et al. 2009. Significantly modified dopaminergic and glutamatergic neurotransmission in the striatum
after selective COX-2 inhibition in normal and parkinsonian rats. Parkinsonism & related disorders Congress Germany 2008
accepted.
[18] Shafiee Ardestani M et al. 2008. Effects of COX-2 and COX-2 gene expression inhibitors on memory-movement
disorders and hippocampus-striatal cholinergic and glutamatergic neurotransmission.
Journal of Volume 4, Issue 4, 1Alzheimer's and Dementia
, July, Pages 768-772

[19] Shafiee Ardestani M et al. 2009. Parkinson's disease, Radiology and Molecular Imaging; an Overview on the Recent
Researches. Accepted in 9 th International Congress on AD-PD disorders. Czech Republic, Prague. Accepted
[20] Shafiee Ardestani M et al 2009. DEXAMETHASONE SIGNIFICANTLY MODIFIED STRIATAL DOPAMINERGIC,
GLUTAMATERGIC AND GABAERGIC NEUROTRANSMISSIONS IN NORMAL AND RAT MODEL OF
PARKINSON'S DISEASE. 9 th International Congress on AD-PD disorders. Czech Republic, Prague. Accepted
[21] Shafiee Ardestani M et al; 2008 HPLC determination of logarithm of octanol-water partition coefficient (log-p)
Iranian J Pharm Sci [Accepted]
[22] Shafiee Ardestani M et al;2008. Synthesis, in vitro and in vivo evaluations of 99m Tc-DTPA-deoxyglucoseamine
and 99m Tc-DTPA-(deoxyglucoseamine) 2 as novel modalities for tumor imaging. Iranian J Pharm Sci [Accepted]
[23] Shafiee Ardestani M et al; 2008. Selective COX-2 but not COX-1 inhibition has controversial effects on Striatal
neurotransmissions in normal and parkinsonian rats. Iranian J Pharm Sci [Accepted]
[24] Shafiee Ardestani M et al 2008. Dexamethasone causes to significant changes in striatal neurotransmissions without
having any improving effect on damaged neurons in normal and parkinsonian rats. [Under revision] Parkinson's Disease.
[25] Shafiee Ardestani M et al 2009. A new class of MRI striatal dopaminergic receptor imaging agents. Submitted to XIX th
IAGG World Congress of Gerontology and Geriatrics , Paris, France. (Accepted)
[26] Shafiee Ardestani M et al 2009. Gd 3+ -DTPA-(Levodopa) 2 as a novel MRI striatal dopaminergic receptor imaging agent;
Synthesis and preclinical evaluations. XXXVI International Congress of Pharmaceutical Sciences. Kyoto, Japan. (Accepted /and
/selected for receiving 100000 Japanese yen as award)
[27] Shafiee Ardestani M et al 2009. Dexamethasone causes significant changes in striatal neurotransmissions without having
any improving effect on damaged neurons. XXXVI International Congress of Pharmaceutical Sciences. Kyoto, Japan. (Accepted)
[28] Shafiee Ardestani M et al 2009. Striatal neurotransmission changes COX-2 inhibition dependent causes to improve the
Parkinson's disease affiliated signs without having any improving effects on SNc damaged neurons. XXXVI International
Congress of Pharmaceutical Sciences. Kyoto, Japan (Accepted)
[29] Shafiee Ardestani M et al 2009. A letter on the published article in the journal of applied radiation and isotopes 64 (2006)
342–347; we should further attend on the publications. Under Challenge in Journal of APPLIED RADIATION AND
ISOTOPES.
[30] Shafiee Ardestani M et al. 2009. Alzheimer's disease or Parkinson's disease , which of them are more difficult for medical
imaging?. Accepted for presentation in ASN-2009[American Society for Neurosciences] Chicago, United States of America,
2009
[31] Shafiee Ardestani et al. 2010. Parkinson's disease, Radiology and Molecular Imaging; an Overview on the Recent
Researches. Accepted in AmericanJournal of Medical Sciences.
[32]. Shafiee Ardestani et al.2010. Novel and facile methods for the synthesis of DTPA -
mono-amide; a new completely revised strategy in Radiopharmaceutical Chemistry.
Journal of Radioanalytical and Nuclear Chemistry. 283: 447–455. part of my PhD thesis]
[33]. Shafiee Ardestani et al. 2009. Mn 2+ or Gd 3+ -Deferasirox-D-Deoxyglucosamine complexes
as novel tumor Magnetic Resonance Imaging agents. Submitted to Bioconjugate Chemistry [A part of my PhD
thesis]

[34]. Shafiee Ardestani et al. 2009. NOVEL APPROACHES IN VIABLE TUMOR MR IMAGING;
BIFUNCTIONAL GADOLINIUM LOADED GLYCOSILATED COMPOUNDS. Submitted to Nature Chemical
Biology [ A part of my PhD thesis]
[35]. Shafiee Ardestani et al. 2010. Anionic linear-globular dendrimer-cis-platinum (II)
conjugates promote cytotoxicity in vitro against different cancer cell lines. International
Journal of Nanomedicine. 15 63–75.
[36] Shafiee Ardestani et al. 2010. Anionic linear-globular dendrimers: biocompatible hybrid
4 materials with potential uses in nanomedicine. Journal of Materials Sciences, Materials in Medicine,
21(4):1121-33.
[37] Shafiee Ardestani et al. 2010. Gd3+-DTPA-DG; a new successful MR viable tumor imaging agent
Accepted in : Contrast Media and Molecular Imaging
[39] Shafiee Ardestani M et al. 2010. Evaluation of the role of striatal cannabinoid CB1
receptors on movement activity of parkinsonian rats induced by reserpine. Published
online in Saudi Pharmaceutical Journal. 18; 4: 207‐215.
[40] Shafiee Ardestani M et al. 2010. New suggesting mechanisms of dexamethasone action
on striatal neurotransmissions. Accepted in Chemical and Pharmaceutical Bulletin
[41] Shafiee Ardestani M et al. 2010. A study of striatal cannabinoid CB 1 receptor's role on
movement activity of parkinsonian rats. Accepted World Pharma 2010.
[42] Shafiee Ardestani M et al. 2010. Dose radiopharmaceutical sciences make sense/ cover
on MRI molecular contrast agents or not? Current Radiopharmaceuticals.3; 4: 284-287
[43] Shafiee Ardestani M et al. 2010. Magnetic Resonance Contrast Media Sensing In Vivo
Molecular Imaging Agents: An Overview. Accepted in Current Radiopharmaceuticals.
[44] Shafiee Ardestani M et al. 2010. The Selective Cyclooxygenase-2 inhibitor the compound
11b improves haloperidol induced catatonia by enhancing the Striatum dopaminergic
neurotransmission. Accepted in Iranian Journal of Pharmaceutical Research.
[45] Shafiee Ardestani M 2010. Novel Radiopharmaceuticals suggested for molecular
imaging. Pharmacie Globale (IJCP); 1:1-4.
[46] Shafiee Ardestani M et al. 2010. A Comparative Study Between the Antibacterial Effect
of Nisin and Nisin-Loaded Chitosan/Alginate Nanoparticles on the Growth of Staphylococcus
aureus in Raw and Pasteurized Milk Samples . Probiotics and Antimicrobial peptides;Volume
2, Number 4, 258-266.
[47] Shafiee Ardestani M. Potential Opponent for 18FDG: Gd3+-DTPA-DG: A New
Synthetic MRI Contrast Agent. Iranian Journal of Radiology 2010;7(S1) : 56
[48] Shafiee Ardestani M et al 2010. Towards β-globin gene-targeting with integrasedefective
lentiviral vectors. Biotechnol Lett. 32(11):1615-21
[49] Shafiee Ardestani M. 2010. Parkinsons disease, the inflammatory pathway and
anti-inflammatory drugs: An Overview. J. Med. Sci., 10: 49-58.

[50] Shafiee Ardestani M et al., Design, modeling, expression, and
chemoselective Pegylation of a new nanosize cysteine analog of
erythropoietin. International Journal of Nanomedicine 2011, 6 accepted and in press..
[51] Shafiee Ardestani M et al., Gd-DTPA-DG: novel nanosized dual anticancer
and molecular imaging agent.. International Journal of Nanomedicine 2011, 6: 747-764..
Language Skills
TOLIMO certification in English 7 October 2005 .
MCHE certification in English 18.5.2006 .
MCHE certification in English 7.12.2006
MCHE certification in English 12.10.2008 [81/100]
Areas of interest
-Gene Tageting
- Nano-drug Targeting
-
- Targeted MRI imaging using bioconjugated compounds labeled with Gadolinium
-Assessment of tissue distribution and drug pharmacokinets by means of Positron Emission Tomography (PET) &
Magnetic Resonance Imaging (MRI)
- Improving the methodology which are used in Radiopharmacy and related analytical studies
-Using radiopharmaceutical science in combination with other related pharmaceutical sciences such as
pharmacological or medicinal chemistry researches
-Receptor Imaging
-Gene Imaging
-Instrumental Chemical & Radiochemical analysis
-Production of Molecular Contrast Media Agents as Novel opponent for MRI imaging
-Pharmacokinetic parameter determination using MRI
-Liposom & Polymer labeling for MRI imaging
American Chemical Society
International Associations and sites
MedScape Pharmacists.
Careplace group
Indian Society of Pharmacology
Pub Med Central.
National Association
Iranian Medicinal Council .
UK Radiopharmacy Group
Iranian Pharmacists association .
Memberships
Hobby
Sport (Basketball & Football), Traveling, and Taking Pictures

References:
Professor Dr. Moghaddam
/ Department of Physiology & Physiology Research Center, School of Medicine, Jondishapour University of
Medical Sciences, Ahwaz, Iran
To whom correspondence should be addressed at:
hfmoghadam@yahoo.com
Dr M. Amanlou
Associated professor of Medicinal Chemistry, Department of Medicinal Chemistry and Radiopharmacy, Faculty of
Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
To whom correspondence should be addressed at:
amanlou@sina.tums.ac.ir
Dr SE. Sadat Ebrahimi
Associated professor of Medicinal Chemistry, Department of Medicinal Chemistry and Radiopharmacy, Faculty of
Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
To whom correspondence should be addressed at:
sesebrahimi@yahoo.com
My non native advisors from United States of America (USA):
Professor Dr Abbas Alavi
Professor Dr Kenneth N Raymond
Professor Dr Wahl
Professor Dr Rahmim